Market Overview:
The global gastroesophageal reflux disease (GERD) therapeutics market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of GERD, rising awareness about GERD and its treatment options, and technological advancements in the field of gastroenterology. The market is segmented on the basis of type into antacids, pro-kinetic agents, H2 receptor blockers, and proton pump inhibitors (PPIs). The PPIs segment is expected to grow at a CAGR of 6.0% from 2018 to 2030 due to their high efficacy and safety profile. On the basis of application, the market is divided into heartburn and acid reflux disorders.
 Therapeutics Industry Outlook.svg)
Product Definition:
Gastroesophageal reflux disease (GERD) is a chronic digestive disorder that happens when stomach acid or food flows back up into the esophagus. GERD can happen to anyone, but it's more common in people who are overweight or pregnant, have a hiatal hernia, smoke, or take certain medications. Symptoms include heartburn, chest pain, regurgitation of food and acid reflux. If left untreated over time GERD can lead to Barrett's esophagus which is a precancerous condition. Gastroesophageal reflux disease (GERD) therapies are used to treat the symptoms of GERD and may help prevent Barrett's esophagus from developing.
Antacids:
Antacids are medications used for neutralizing the acid produced by the stomach. They are available in various forms such as tablets, powders, and liquids. Antacids can be purchased over-the-counter or with a prescription from a healthcare provider. The most common type of antacid is magnesium trisilicate which provides an aluminum foil packet containing an antacid that dissolves to release its contents into the stomach.
Pro-kinetic agents:
Pro-kinetic agents are a group of drugs that delays the emptying rate of the stomach and thus increases its capacity to hold food. This results in delayed gastric emptying thereby increasing the time for acid reflux to occur. Pro-kinetic agents act by different mechanisms namely, by either decreasing or delaying gastric Emptying Time (GET) or prolonging Alkaline Phosphatase (AP) peak height in blood.
Application Insights:
The heartburn segment dominated the global gastroesophageal reflux disease therapeutics market in 2017. This is due to the increasing prevalence of lifestyle disorders and growing awareness about available treatment options. As per a study published by NCBI, around 45% of adults suffer from heartburn at least once a month. PPI therapy is considered to be first-line treatment for GERD as it has fewer side effects as compared with other drugs such as H2 receptor antagonists or antacids.
PPIs are highly effective against acid reflux and have few adverse effects; therefore, they are being widely used for treating various types of GERD including Zollinger-Ellison syndrome, chronic idiopathic constipation, and hiatal hernia among others.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the high prevalence of GERD, increasing awareness about its treatment options, and availability of highly effective and safer prescription drugs. Moreover, growing R&D investments by major companies for development of novel therapeutics is also expected to drive growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative CAGR over the forecast period owing to rising geriatric population base that's prone to various diseases along with increasing disposable income resulting in improved healthcare facilities & infrastructure. Furthermore, economic development coupled with improvement in living standards has led people from lower socio-economic groups toward higher education leading towards a better standard of living which includes accesses health care facilities & services thus driving demand for PPI therapy among middle-income countries such as India and China over the forecast period (2018 - 2030).
Growth Factors:
- Increasing prevalence of GERD
- Growing awareness about the symptoms and treatment of GERD
- Rising demand for better and more effective therapies for GERD
- Availability of novel drugs and therapies for the treatment of GERD
- Growing number of clinical studies on new treatments for GERD
Scope Of The Report
Report Attributes
Report Details
Report Title
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Research Report
By Type
Antacids, Pro-kinetic agents, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs)
By Application
Heartburn, Acid reflux disorders
By Companies
AstraZeneca, Eisai, GSK, Takeda, Johnson & Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
183
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Report Segments:
The global Gastroesophageal Reflux Disease (GERD) Therapeutics market is segmented on the basis of:
Types
Antacids, Pro-kinetic agents, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Heartburn, Acid reflux disorders
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Eisai
- GSK
- Takeda
- Johnson & Johnson
 Therapeutics Market Overview.svg)
Highlights of The Gastroesophageal Reflux Disease (GERD) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antacids
- Pro-kinetic agents
- H2 Receptor Blockers
- Proton Pump Inhibitors (PPIs)
- By Application:
- Heartburn
- Acid reflux disorders
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gastroesophageal Reflux Disease (GERD) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gastroesophageal reflux disease (GERD) therapeutics are medications used to treat GERD. These medications work by reducing the amount of acid that flows back up from the stomach and into the esophagus.
Some of the key players operating in the gastroesophageal reflux disease (gerd) therapeutics market are AstraZeneca, Eisai, GSK, Takeda, Johnson & Johnson.
The gastroesophageal reflux disease (gerd) therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gastroesophageal Reflux Disease (GERD) Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gastroesophageal Reflux Disease (GERD) Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Y-o-Y Growth
4.5.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Antacids
5.2.2 Pro-kinetic agents
5.2.3 H2 Receptor Blockers
5.2.4 Proton Pump Inhibitors (PPIs)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Heartburn
6.2.2 Acid reflux disorders
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Antacids
9.6.2 Pro-kinetic agents
9.6.3 H2 Receptor Blockers
9.6.4 Proton Pump Inhibitors (PPIs)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Heartburn
9.10.2 Acid reflux disorders
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Antacids
10.6.2 Pro-kinetic agents
10.6.3 H2 Receptor Blockers
10.6.4 Proton Pump Inhibitors (PPIs)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Heartburn
10.10.2 Acid reflux disorders
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Antacids
11.6.2 Pro-kinetic agents
11.6.3 H2 Receptor Blockers
11.6.4 Proton Pump Inhibitors (PPIs)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Heartburn
11.10.2 Acid reflux disorders
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Antacids
12.6.2 Pro-kinetic agents
12.6.3 H2 Receptor Blockers
12.6.4 Proton Pump Inhibitors (PPIs)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Heartburn
12.10.2 Acid reflux disorders
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Antacids
13.6.2 Pro-kinetic agents
13.6.3 H2 Receptor Blockers
13.6.4 Proton Pump Inhibitors (PPIs)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Heartburn
13.10.2 Acid reflux disorders
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Market: Competitive Dashboard
14.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Eisai
14.3.3 GSK
14.3.4 Takeda
14.3.5 Johnson & Johnson
